A Peer-Reviewed Academic Journal for Pharmacology, Pharmacotherapeutics, Clinical Pharmacy, Medication Safety, and Therapeutics
Search, filter, and explore research contributions across pharmacology, pharmacotherapeutics, and clinical pharmacy
The journal is currently in its inaugural peer-review and manuscript preparation phase. No genuine peer-reviewed articles have been officially published in this catalog yet. Accepted manuscripts will appear in this index continuously as peer review is completed.
[Demo Author A - PharmD Placeholder], [Demo Author B - MD Placeholder], [Demo Author C - PhD Placeholder]
[DEMO CONTENT] Individualized dosage adjustment using therapeutic drug monitoring (TDM) is essential for maximizing therapeutic outcomes while minimizing toxicities. This simulated article illustrates the structured abstract layout for research manuscripts submitted to the journal.
[Demo Reviewer A - PharmD Placeholder], [Demo Reviewer B - MD Placeholder]
[DEMO CONTENT] Adverse drug reactions (ADRs) are a major cause of preventable hospital morbidity and prolonged inpatient stay. This demonstration review illustrates the layout for comprehensive literature syntheses.
Disciplines and areas of scientific inquiry currently welcomed for Volume 1:
Human pharmacology, phase I-IV trials, drug metabolism, PK/PD modeling, and therapeutic drug monitoring.
Clinical outcomes, guideline-directed medical therapies, pharmacotherapy protocols, and comparative effectiveness.
Hypertension, heart failure, dyslipidemia, diabetes mellitus, and endocrine therapeutic interventions.
Antibiotic resistance, dosing regimens in sepsis, antifungal therapies, and viral management.
We invite clinicians, pharmacologists, and clinical pharmacists to submit their original investigations, observational studies, or systematic reviews for consideration in Volume 1.
Medication safety, clinical pharmacist interventions, patient counseling, and rational drug utilization.
Adverse drug reactions, signal detection, risk management plans, and post-marketing safety data.
Biologics, monoclonal antibodies, small molecule kinase inhibitors, and toxicities associated with chemotherapy.
Central nervous system therapeutics, psychotropic agents, neurodegenerative interventions, and analgesics.